Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83

Computational methods in drug discovery. Pharmacol Rev (2013) 1.51

Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol Cell Proteomics (2011) 1.18

Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget (2011) 0.91

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem Neurosci (2012) 0.91

Hepcidin and the iron enigma in HCV infection. Virulence (2014) 0.88

Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity. Mol Cell Biol (2011) 0.87

Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2. J Proteome Res (2011) 0.85

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours. Nat Commun (2015) 0.81

Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. Cell Mol Life Sci (2011) 0.81

Understanding protein kinase CK2 mis-regulation upon F508del CFTR expression. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.79

Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization. Sci Signal (2015) 0.79

The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation. Biomed Res Int (2015) 0.78

The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design. Pharmaceuticals (Basel) (2017) 0.78

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals (Basel) (2017) 0.78

Halogenated imidazole derivatives block RNA polymerase II elongation along mitogen inducible genes. BMC Mol Biol (2010) 0.78

Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation. PLoS One (2014) 0.77

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells. PLoS One (2014) 0.75

Identification of quinones as novel PIM1 kinase inhibitors. Bioorg Med Chem Lett (2016) 0.75

Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a new Alzheimer's disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme. Int J Mol Sci (2015) 0.75

Tracking down biotransformation to the genetic level: identification of a highly flexible glycosyltransferase from Saccharothrix espanaensis. Appl Environ Microbiol (2013) 0.75

Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. Heliyon (2017) 0.75

Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab (2005) 8.30

The specificities of protein kinase inhibitors: an update. Biochem J (2003) 7.76

One-thousand-and-one substrates of protein kinase CK2? FASEB J (2003) 6.89

Feeding aquaculture in an era of finite resources. Proc Natl Acad Sci U S A (2009) 4.11

FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11

Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J (2004) 3.39

The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell (2004) 2.46

Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum (2008) 2.45

Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31

D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep (2004) 2.31

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J (2007) 2.11

Tiger snake (Notechis spp) envenoming: Australian Snakebite Project (ASP-13). Med J Aust (2012) 2.04

BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem (2005) 1.95

Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta (2009) 1.95

Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest (2005) 1.93

The mitochondrial calcium uniporter is a multimer that can include a dominant-negative pore-forming subunit. EMBO J (2013) 1.86

The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity (2005) 1.85

Secreted protein kinases. Trends Biochem Sci (2012) 1.79

Aurora-A site specificity: a study with synthetic peptide substrates. Biochem J (2005) 1.77

2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun (2004) 1.70

USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol (2011) 1.61

Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J (2002) 1.60

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett (2011) 1.55

Salicylic acid activates nitric oxide synthesis in Arabidopsis. J Exp Bot (2007) 1.47

The selectivity of inhibitors of protein kinase CK2: an update. Biochem J (2008) 1.45

Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol (2004) 1.43

Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood (2006) 1.37

Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem (2007) 1.37

A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins. Proc Natl Acad Sci U S A (2003) 1.36

Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem (2008) 1.32

Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem (2004) 1.26

Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J (2003) 1.22

Protein kinase CK2 inhibitors: a patent review. Expert Opin Ther Pat (2012) 1.21

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy (2014) 1.21

Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta (2009) 1.20

Structure of the neutrophil-activating protein from Helicobacter pylori. J Mol Biol (2002) 1.19

Structure of two iron-binding proteins from Bacillus anthracis. J Biol Chem (2002) 1.16

Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry (2004) 1.16

Protein kinase CK2 as a druggable target. Mol Biosyst (2008) 1.16

Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood (2006) 1.15

Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther (2002) 1.15

Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood (2008) 1.13

pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem (2008) 1.11

Crystal structure of amine oxidase from bovine serum. J Mol Biol (2005) 1.11

Structure-function analysis of yeast piD261/Bud32, an atypical protein kinase essential for normal cell life. Biochem J (2002) 1.09

MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol (2011) 1.09

Chemical dissection of the APC Repeat 3 multistep phosphorylation by the concerted action of protein kinases CK1 and GSK3. Biochemistry (2007) 1.06

Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci (2009) 1.06

Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci (2004) 1.06

The neutrophil-activating protein of Helicobacter pylori. Int J Med Microbiol (2002) 1.05

Functional homology between yeast piD261/Bud32 and human PRPK: both phosphorylate p53 and PRPK partially complements piD261/Bud32 deficiency. FEBS Lett (2003) 1.04

Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J (2003) 1.04